Inform Diagnostics News Today

Director/Board Member at Rallybio Corp., Discover Ron Hunt's known position history, network and 100 relationships. Find out about his known public assets.

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call Transcript February 28, 2024 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.28, expectations were $-0.3. Fulgent Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to […]

For El Monte-based clinical diagnostic testing company Fulgent Genetics Inc., the Covid testing surge that catapulted the company from $32 million in annual revenue to the doorstep of $1 billion in just two years has now all but ended.

/PRNewswire/ -- Synthetica Bio, a privately held healthcare technology company developing an enterprise-grade, generative artificial intelligence (GenAI)...

The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007 in treating various types of cancer. See why FLGT stock is a Hold.

Operator: Hello and welcome to the Fulgent Genetics Q1 2023 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Operator: Hello and welcome to the Fulgent Genetics Q4 and Fiscal Year 2022 Earnings Conference Call and Webcast. As a reminder, this conference is being recorded.

On November 1, 2022, the Department of Justice ("DOJ") announced that Florida-based electronic health record ("EHR") vendor, Modernizing Medicine ("ModMed")...

The U.S. Department of Justice alleges that the EHR vendor accepted and provided "unlawful remuneration in exchange for referrals and by causing its users to report inaccurate information in connection with claims for federal incentive payments."

Learn more about Fulgent Genetics’ share price tumbling as Covid test revenue falls and the company’s plans for a post-Covid testing strategy.